Daily costs of hospitalization in non-valvular atrial fibrillation patients treated with anticoagulant therapy

References

• Go AS, Hylek EM, Phillips KA, et al. Prevalence of diagnosed atrial fibrillation in adults: national implications for rhythm management and stroke prevention: the AnTicoagulation and Risk Factors in Atrial Fibrillation (ATRIA) Study. JAMA 2001;285:2370-5
   PubMed Web of Science ®Google Scholar
• Miyasaka Y, Barnes ME, Gersh BJ, et al. Secular trends in incidence of atrial fibrillation in Olmsted County, Minnesota, 1980 to 2000, and implications on the projections for future prevalence. Circulation 2006;114:119-25
   PubMed Web of Science ®Google Scholar
• Naccarelli GV, Varker H, Lin J, et al. Increasing prevalence of atrial fibrillation and flutter in the United States. Am J Cardiol 2009;104:1534-9
   PubMed Web of Science ®Google Scholar
• Ball J, Carrington MJ, McMurray JJ V, et al. Atrial fibrillation: profile and burden of an evolving epidemic in the 21st century. Int J Cardiol 2013;167:1807-24
   PubMed Web of Science ®Google Scholar
• Go AS, Mozaffarian D, Roger VL, et al. Heart disease and stroke statistics–2013 update: a report from the American Heart Association. Circulation 2013;127:e6-e245
   PubMed Web of Science ®Google Scholar
• Wu EQ, Birnbaum HG, Mareva M, et al. Economic burden and co-morbidities of atrial fibrillation in a privately insured population. Curr Med Res Opin 2005;21:1693-9
   PubMed Web of Science ®Google Scholar
• Coyne KS, Paramore C, Grandy S, et al. Assessing the direct costs of treating nonvalvular atrial fibrillation in the United States. Value health j Int Soc Pharmacoecon Outcomes Res 2006;9:348-56
   Web of Science ®Google Scholar
• Kim MH, Johnston SS, Chu B-C, et al. Estimation of total incremental health care costs in patients with atrial fibrillation in the United States. Circulation. Cardiovasc Qual Outcomes 2011;4:313-20
   PubMed Web of Science ®Google Scholar
• Mantha S, Cabral K, Ansell J. New avenues for anticoagulation in atrial fibrillation. Clin Pharmacol Therapeut 2013;93:68-77
   PubMed Web of Science ®Google Scholar
• U.S. Food and Drug Administration. FDA approves Pradaxa to prevent stroke in people with atrial fibrillation. Silver Spring, MD, 2010. http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm230241.htm. Accessed January 2014.
   Google Scholar
• U.S. Food and Drug Administration. FDA approves Xarelto to prevent stroke in people with common type of abnormal heart rhythm. Silver Spring, MD, 2011. http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm278646.htm. Accessed January 2014.
   Google Scholar
• U.S. Food and Drug Administration. FDA approves Eliquis to reduce the risk of stroke, blood clots in patients with non-valvular atrial fibrillation. Silver Spring, MD, 2012. http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm333634.htm. Accessed January 2014.
   Google Scholar
• Hankey GJ, Eikelboom JW. Novel oral anticoagulants for atrial fibrillation. Curr Atheroscler Rep 2013;15:344
   PubMed Web of Science ®Google Scholar
• Fonseca E, Walker DR, Hill J, et al. Abstract 282: Dabigatran Etexilate is associated with shorter hospital length of stay compared to Warfarin in patients with nonvalvular atrial fibrillation. Circ Cardiovasc Qual Outcomes 2012;5:A282
   Google Scholar
• Laliberté F, Pilon D, Raut MK, et al. Hospital length of stay: is rivaroxaban associated with shorter inpatient stay compared to warfarin among patients with non-valvular atrial fibrillation? Curr Med Res Opin 2014;30:645-53
   PubMed Web of Science ®Google Scholar
• Cowper PA, Pan W, Anstrom K, et al. Apixaban reduces hospitalization in patients with atrial fibrillation: an analysis of the effect of Apixaban therapy on resource use in the Apixaban for reduction in stroke and other thromboembolic events in atrial fibrillation trial. J Am Coll Cardiol 2013;61:E1576
   Web of Science ®Google Scholar
• Dasta JF, Pilon D, Mody SH, et al. Daily hospitalization costs in patients with deep vein thrombosis or pulmonary embolism treated with anticoagulant therapy. Thromb Res 2015;135:303-10
   PubMed Web of Science ®Google Scholar
• Cohen J. Statistical power analysis for the behavioral sciences. New York, NY: Toronto Academic Press, Inc, 1977
   Google Scholar
• Normand ST, Landrum MB, Guadagnoli E, et al. Validating recommendations for coronary angiography following acute myocardial infarction in the elderly: a matched analysis using propensity scores. J Clin Epidemiol 2001;54:387-98
   PubMed Web of Science ®Google Scholar
• Austin PC. Using the standardized difference to compare the prevalence of a binary variable between two groups in observational research. Commun Stat Simul Comput 2009;38:1228-34
   Web of Science ®Google Scholar
• 3M. M Health Information Systems - US. APR DRG Software. Salt Lake City, UT: 3M, 2013. http://solutions.3m.com/wps/portal/3M/en_US/Health-Information-Systems/HIS/Products-and-Services/Products-List-A-Z/APR-DRG-Software/. Accessed January 2014.
   Google Scholar
• Song X, Sander SD, Johnson BH, et al. Impact of atrial fibrillation and oral anticoagulation on hospital costs and length of stay. AJHP Off J Am Soc Health-Syst Pharm. 2012;69:329-38
   PubMed Web of Science ®Google Scholar
• Fonseca E, Walker DR, Hess GP. Abstract 258: Dabigatran Etexilate is associated with shorter hospital length of stay and lower hospital costs compared to Warfarin in treatment-naive, newly-diagnosed nonvalvular atrial fibrillation patients. Circulation: Cardiovasc Qual Outcomes 2013;6:A258
   Google Scholar
• Arowolaju A, Gillum RF. A new decline in hospitalization with atrial fibrillation among the elderly. Am J Med 2013;126:455-7
   PubMed Web of Science ®Google Scholar
• Farr A, Jing Y, Johnston S, et al. Abstract 16698: comparison of hospital length of stay between hospitalized non-valvular atrial fibrillation patients treated with either Apixaban or Warfarin. Circulation 2014;130(2 Suppl):A16698
   Google Scholar
• Wong CX, Lau DH, Sanders P. Atrial fibrillation epidemic and hospitalizations how to turn the rising tide? Circulation 2014;129:2361-63
   PubMed Web of Science ®Google Scholar